New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
07:34 EDTRNAProsensa upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Prosena following new encouraging subset data analysis of lead drug drisapersen and full ownership potential following termination of its partnership with GlaxoSmithKline. Price target raised to $12 from $7.
News For RNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
08:36 EDTRNAProsensa intends to voluntarily delist from NASDAQ
Subscribe for More Information
08:34 EDTRNAProsensa intends to voluntarily delist from NASDAQ

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use